Stereotaxis' Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011

ST. LOUIS, May 4, 2011 /PRNewswire/ -- Stereotaxis' (Nasdaq: STXS) continued leadership in the remote treatment of a broad spectrum of complex arrhythmias will again be prominently detailed in the scientific program of the 32nd Annual Heart Rhythm Scientific Sessions in San Francisco, California. Ten podium presentations and ten posters will feature clinical data and discussions of the value of magnetic navigation in the treatment of a variety of abnormal heart rhythms. Stereotaxis will display its advanced tools for the electrophysiology lab in booth # 2202 and will host multiple invitation-only scientific sessions for both current users as well as potential customers.

In addition, Stereotaxis will introduce its new electrophysiology platform: Epoch™. The Stereotaxis Epoch platform is designed to increase efficiency in electrophysiology procedures with a fully-remote, networked and modular robotic and magnetic solution.

ATRIAL FIBRILLATION

Atrial fibrillation is the most common abnormal heart rhythm and is increasing in incidence along with the aging population.  Two prominent centers from the United States will be detailing their results using Stereotaxis magnetic navigation for patients with atrial fibrillation. Dr. Andrea Natale and colleagues from Texas Cardiac Arrhythmia Institute in Austin, Texas will be presenting an abstract entitled "Remote Magnetic Navigation for Atrial Fibrillation with the Open Irrigated Catheter: Single Center Experience in a Randomized Study" during Poster Session #5 on Friday, May 6th beginning at 2:00 PM.  Dr. Raul Weiss and colleagues from The Ohio State University will be presenting an abstract entitled "Outcomes with Remote Magnetic Navigation for Ablation of Atrial Fibrillation" during Poster Session #6 on Saturday, May 7th beginning at 9:00 AM.  

Additional safety data will be presented in the Poster Session #5 by Prof. Karl-Heinz Kuck and colleagues from the Asklepios Klinik St Georg in Hamburg, Germany in an abstract entitled "Remote-Controlled Magnetic Pulmonary Vein Isolation Vs Manual Pulmonary Vein Isolation: Luminal Esophageal Temperature Rise and Esophageal Lesion Formation." All of these sessions will be held in the main exhibit hall.

VENTRICULAR TACHYCARDIA

Ventricular tachycardia is a potentially life-threatening heart rhythm disorder that originates in the lower chambers of the heart.  Several centers will be detailing the unique value of Stereotaxis in the treatment of ventricular arrhythmias.  A podium presentation entitled "Catheter Ablation of Scar-Related Monomorphic Ventricular Tachycardia Using Remote Magnetic Catheter Navigation: A Case-Control Study" will be presented by Dr. Borislav Dinov from the Herzzentrum Leipzig in Leipzig, Germany on Thursday, May 5th at 2:15 PM in Room 2010 Moscone West.  Hiroshi Nakagawa, MD, PhD, Co-Director of the Heart Rhythm Institute at the University of Oklahoma Health Sciences Center will deliver a podium presentation titled "Catheter Ablation of Ventricular Tachycardia Associated with Prior Myocardial Infarction: High-Density Mapping and Ablation of Isolated Late Potentials Using Magnetic Catheter Maneuvering System," on Saturday, May 7th, at 11:10 AM in Room 304 of Moscone South.

Additionally, Petr Neuzil, MD, PhD, from Na Holmoce Hospital in Prague, will present an abstract entitled "STOP-VT: A Multi-Center Trial to Evaluate Radiofrequency Ablation with Magnetic Navigation for Ischemic Ventricular Tachycardia" on behalf of the STOP-VT investigators during Poster Session 6 on Saturday, May 7th beginning at 9:00 AM in the main exhibit hall.

SUPRAVENTRICULAR TACHYCARDIA

Supraventricular tachycardia is a term used to describe several commonly experienced abnormal heart rhythms that occur in the heart's upper chambers and may represent a significant percentage of an electrophysiologist's practice.  Dr. Mauricio Arruda from the Case Western Reserve University School of Medicine in Cleveland, Ohio will deliver a podium presentation entitled "Is There a Role for Magnetic Navigation in SVT?" on Friday, May 6th at 8:24 AM in Room 2002 Moscone West.

CONGENITAL DEFECTS

Patients who have had surgery to repair congenital heart defects during their childhood often develop abnormal heart rhythms during their adult lives, presenting a significant challenge to the treating electrophysiologist.  Dr. Tamas Szili-Torok and colleagues from the Thoraxcenter at Erasmus Medical Center in Rotterdam, The Netherlands will present the paper, "Remote Magnetic Navigation is a Highly Effective Method for Ablation of Arrhythmias in Patients with Complex Congenital Heart Disease" on Friday, May 6th  during Poster Session #4 beginning at 9:00 AM in the main exhibit hall.

"The Heart Rhythm Society meeting represents the key clinical and educational forum for practicing electrophysiologists worldwide," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis.  "Stereotaxis' prominent position on the scientific program further underscores our exceptional value for patients with heart rhythm disorders and signifies our continued commitment to the field of cardiac electrophysiology."

About Stereotaxis             www.stereotaxis.com         www.odysseyexperience.com

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. The Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. The Odyssey™ Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  The Odyssey™ solution then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to,   continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE Stereotaxis